AstraZeneca launches US$1.5bil annual savings plan to invest in drug pipeline
Drugmakers worldwide face growing scrutiny over their research pipelines, as valuations increasingly depend on successful late-stage trials rather than blockbuster drugs nearing patent expiry.
We haven't written up this one. Free Malaysia Today has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- AstraZeneca launches US$1.5bil annual savings plan to invest in drug pipeline freemalaysiatoday.com
